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A fundamental goal in biology is to understand the molecular
basis of cell identity. Pluripotent embryonic stem (ES) cell
identity is governed by a set of transcription factors centred on
the triumvirate of Oct4, Sox2 and Nanog. These proteins often
bind to closely localised genomic sites. Recent studies have
identified additional transcriptional modulators that bind to
chromatin near sites occupied by Oct4, Sox2 and Nanog. This
suggests that the combinatorial control of gene transcription
might be fundamental to the ES cell state. Here we discuss how
these observations advance our understanding of the
transcription factor network that controls pluripotent identity
and highlight unresolved issues that arise from these studies.
Introduction
Pluripotency is the capacity of a cell to give rise to differentiated
derivatives that represent each of the three primary germ layers.
Pluripotency is a property of the cells that are located within the
inner cell mass (ICM) of the developing blastocyst. These cells can
be explanted and embryonic stem (ES) cell lines established from
them that can be cultured in vitro, essentially indefinitely. The
maintenance of pluripotent identity requires either the stimulation of
mouse ES cells by leukemia inhibitory factor (LIF) and by bone
morphogenetic protein (BMP) or the treatment of cells with a
cocktail of enzyme inhibitors, which are thought to block the action
of pro-differentiative signals generated autonomously by ES cells
(for reviews, see Chambers and Smith, 2004; Silva and Smith,
2008). ES cells possess many features that make them attractive for
studying the molecular basis of cell identity (Box 1). Functional
studies have been of central importance in identifying a group of
transcription factors that affect the pluripotent identity of ES cells
(Chambers et al., 2003; Chambers et al., 2007; Ema et al., 2008;
Fujikura et al., 2002; Masui et al., 2007; Niwa et al., 2000; Niwa et
al., 2005). Within this group, the transcription factors Oct4 (Pou5f1),
Sox2 and Nanog are crucial for the efficient maintenance of ES cell
identity (Chambers et al., 2007; Masui et al., 2007; Niwa et al.,
2000). During mouse development, the specification of pluripotent
cell identity requires the embryonic genome to express Oct4
(Nichols et al., 1998) and Nanog (Mitsui et al., 2003), but not Sox2
(Avilion et al., 2003), perhaps owing to the presence of long-lived
maternal Sox2 protein (Avilion et al., 2003).
Genome-wide studies have highlighted the colocalisation of Oct4,
Sox2 and Nanog in ES cell chromatin and the existence of a
transcriptional network that might direct ES cell identity (Boyer et
al., 2005; Loh et al., 2006). Subsequent studies have identified
multiple additional transcription factors that colocalise with Oct4,
Sox2 and Nanog (Chen et al., 2008b; Cole et al., 2008; Kim et al.,
2008) and have connected miRNA-encoding genes to this circuitry
(Marson et al., 2008). Such studies have expanded our view of the
transcription factor network that controls the ES cell state and have
generated a wealth of bioinformatic data for further analysis.
Here we review the experiments that have informed our
understanding of the biological function of Oct4, Sox2 and Nanog
in ES cell self-renewal. We discuss experiments that have identified
proteins that interact with these molecules, before addressing the
findings of global chromatin localisation studies. The latter have in
part been informed by parallel studies on the induction of
pluripotency in somatic cells [for recent reviews on induced
pluripotency, we refer the reader to the literature (Hochedlinger and
Plath, 2009; Jaenisch and Young, 2008; Yamanaka, 2007)]. Finally,
we examine unanswered questions that these studies have raised.
DNA-binding characteristics of Nanog, Oct4 and
Sox2
The precise manner in which Nanog, Oct4 and Sox2 interact with
DNA is likely to make a major contribution to their function. Nanog
has a single homeodomain that binds to DNA (Fig. 1A) (Jauch et al.,
2008). The Nanog homeodomain is a variant; although most closely
related to the Nkx family, Nanog is not part of this family. The level
of identity between the Nanog homeodomain and other
homeodomains is below that required for assignment to a particular
family (Kappen et al., 1993). Moreover, sequences that are
conserved among the Nkx family members are absent from Nanog
(Lints et al., 1993). The DNA sequence bound by Nanog is a matter
of some controversy. The in vitro selection of random
oligonucleotides by recombinant Nanog expressed in E. coli has
suggested that Nanog binds to the homeodomain core recognition
sequence TAAT (Mitsui et al., 2003). More detailed DNA-binding
analysis of the purified homeodomain alone has suggested that
Nanog binds to the extended sequence TAATGG (Jauch et al.,
2008). By contrast, results from global localisation studies in ES
cells have suggested that Nanog binds to the sequence CATT (Loh
et al., 2006).
Oct4 belongs to the Octamer class of transcription factors that
recognise an 8-bp DNA site (hence the name) with the consensus
ATGCAAAT (Falkner and Zachau, 1984; Parslow et al., 1984).
Together with Pit and Unc proteins, Oct proteins define the POU
(Pit, Oct and Unc) class of transcription factors that interact with
DNA through two DNA-binding domains (Fig. 1B): a low-affinity
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Box 1. The utility of ES cells in studying the molecular
basis of cell identity
ES cells are defined by the simultaneous possession of the seemingly
incongruent properties of self-renewal and the capacity to
differentiate into cellular derivatives of all primary germ layers.
ES cells can be cultivated in large numbers, facilitating their
biochemical analysis.
ES cells can be readily modified genetically, allowing the effects on
cell identity of altering the intracellular environment to be monitored.
ES cell identity can also be altered by changing the culture conditions,
the effects of which can be monitored and assessed.
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POU-specific domain (POUS) and a higher affinity homeodomain
(POUHD) (Klemm and Pabo, 1996). Each POU domain contacts 4
bp in the major groove of the cognate DNA site, thereby placing
each DNA-binding domain on either side of the helix and effectively
encircling the DNA (Phillips and Luisi, 2000).
Sox2 is a member of a superfamily of proteins that all possess a
High mobility group (HMG) box DNA-binding domain (Fig. 1C).
Sox subfamily members are defined by the relationship of their
HMG box to that of the testes determining factor Sry, the archetypal
Sox protein from which the family takes its name (Sox, Sry HMG
box) (Bowles et al., 2000). The Sox2 HMG domain interacts with
DNA through the minor groove of the consensus sequence
A/TA/TCAAAG (Bowles et al., 2000). Interestingly, a methionine
residue within the Sox2 HMG domain intercalates between bases in
the binding site and acts like a cantilever to cause DNA bending
(Weiss, 2001).
Oct4 and Sox2 bind DNA co-operatively (Ambrosetti et al.,
1997; Ambrosetti et al., 2000). It is noteworthy that at validated
target sites, the non-palindromic Oct4 and Sox2 cognate
sequences always occur adjacent to one another in a particular
relative orientation. Furthermore, the interaction of the POUS
domain with the major groove and of the HMG domain with the
minor groove positions these two DNA-binding domains adjacent
to one another on the same side of the helix (Fig. 2). Although
structural studies of Oct4 and Sox2 bound to DNA have not been
performed, structural analyses of the DNA-binding domains of
Oct1 (Pou2f1) and Sox2 complexed with DNA (Remenyi et al.,
2003; Williams et al., 2004) suggest how Sox2 and Oct4 might
interact with DNA (Fig. 2). Interestingly, analysis of the Oct-DNA
binary complex has revealed the existence of two Oct/DNA
conformations, one in which both DNA-binding domains contact
the DNA, and one in which only the higher affinity POUHD
contacts the DNA (Williams et al., 2004). By contrast, in the Oct-
Sox-DNA ternary complex, the POUS domain was always in
contact with the DNA. This is due to side chains on the Sox2
HMG domain and the Oct POUS domain, which interact with one
another and hold the POUS domain onto the DNA. This study not
only offers an explanation for the relatively inflexible spatial
relationship observed between the non-palindromic DNA
recognition sequences for Oct4 and Sox2 at validated targets, but
also provides an indication of how protein interactions might
begin to build up a stable, multi-protein machine for the
combinatorial control of gene transcription.
In marked contrast to these structural studies, which aim to
provide a view of the transcriptional machinery at atomic resolution,
a recent trend has been to examine the localisation of proteins
throughout chromatin as a means of elucidating the transcriptional
control of cell identity. We discuss these studies in more detail
below. First, we discuss the phenotypic effects on pluripotency of
altering the levels of Nanog, Oct4 and Sox2.
Modulation of Oct4, Sox2 and Nanog
In 2000, a bench-mark study defined the effects on ES cell self-
renewal of altering the dose of a transcription factor, Oct4 (Niwa et
al., 2000). In this study, the self-renewal of Oct4-null mouse ES cells
was sustained by the expression of a tetracycline-suppressible Oct4
transgene. Upon silencing of Oct4 with tetracycline, ES cells
differentiated into trophectoderm, the lineage that supplies
trophoblast cells for the developing placenta (Kunath et al., 2004).
Using the same tetracycline-suppressible transgene in Oct4
heterozygous ES cells, the additional, surprising observation was
made that increasing Oct4 protein levels above ~150% of that in
wild-type ES cells caused differentiation into a mixed population of
cells that express both mesoderm and endoderm markers (Niwa et
al., 2000).
Deletion of Sox2 in ES cells causes a trophectodermal
differentiation phenotype similar to that seen following the deletion
of Oct4 (Masui et al., 2007). A major surprise from these studies
(Masui et al., 2007) was the discovery that the expression of many
Oct/Sox target genes was not greatly affected by the loss of Sox2.
This is probably a consequence of the expression of the additional
Sox family members Sox4, Sox11 and Sox15 in ES cells. The key
distinguishing contribution of Sox2 appears to be to maintain Oct4
expression: consistent with this view is the finding that the enforced
expression of Oct4 can rescue ES cells from differentiation induced
by the loss of Sox2 (Masui et al., 2007). This has been proposed to
reflect the regulation by Sox2 of the genes that encode the
transcription factors Nr5a2 (nuclear receptor subfamily 5, group A,
member 2; also known as Lrh1) and Nr2f2 (nuclear receptor
subfamily 2, group F, member 2; also known as CoupTFII), which
in turn act on Oct4. In addition to these knockout studies, Sox2
overexpression studies have shown that under conditions that favour
differentiation, Sox2-overexpressing ES cells are biased towards
neural differentiation (Kopp et al., 2008; Zhao et al., 2004).
However, whereas a recent study found that under self-renewing
conditions Sox2-overexpressing cells differentiate (Kopp et al.,
2008), this was not observed in an earlier study (Zhao et al., 2004).
Nanog was isolated simultaneously by two groups. In one study,
in silico analysis identified ES cell-specific transcripts, including
Nanog (Mitsui et al., 2003). In our laboratory, expression cloning
from an ES cell cDNA library identified Nanog as a molecule
capable of conferring cytokine-independent self-renewal upon
transfected ES cells (Chambers et al., 2003). Subsequent analyses
have demonstrated that reduction in the level of Nanog increases the
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Fig. 1. Nanog, Oct4 and Sox2 protein domains. Each protein is
divided into domains, either real or putative. DNA-binding domains are
shown in green and regions with reported trans-activating potential in
orange. (A) Nanog can be divided into N-terminal and C-terminal
halves. The N-terminal half contains a DNA-binding homeodomain (HD)
and an N-terminal domain (ND). The C-terminal half contains a
dimerisation domain (blue) referred to as the tryptophan repeat (WR),
in which every fifth residue is a tryptophan (Mullin et al., 2008), that
separates C-terminal domain 1 (CD1) from C-terminal domain 2 (CD2).
(B) Oct4 has DNA-binding domains comprising a POU-specific DNA-
binding domain (POUS) and a POU-homeodomain (POUHD), each of
which can interact independently with DNA (Herr and Cleary, 1995), as
well as transactivation domains located N-terminal (N-TAD) or C-
terminal (C-TAD) to the POU domain. (C) Sox2 is a High mobility group
(HMG) family member and has a single HMG DNA-binding domain and
a transactivation domain (TAD). The size of each protein is indicated in
amino acid residues (aa). Drawings are not to scale.
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propensity of cells to differentiate (Chambers et al., 2007; Hatano et
al., 2005; Ivanova et al., 2006). However, Nanog-null ES cells
continue to self-renew, indicating that the loss of Nanog does not
commit ES cells to differentiation (Chambers et al., 2007). Although
these studies tell us about the consequences for pluripotency of
altering the level of key transcription factors, they do not tell us how
such molecules work.
Identifying Oct4 and Nanog interaction partners
One approach to the question of how transcriptional regulators
function is to use affinity-based methods in combination with mass
spectrometry to identify the proteins with which such regulators
interact. As we discuss below, this approach has identified proteins
that interact with the core pluripotency factors.
In one study, antibodies against genetically unmodified Nanog
protein identified an interaction between Nanog and Smad1 (a signal
transducer in the BMP signalling pathway) (Suzuki et al., 2006). In
addition, an epitope-tagging approach (Fig. 3A), in which a Flag
affinity peptide was fused to the N-terminus of Nanog, allowed
immobilised anti-Flag immunoglobulins to be used to purify Nanog-
containing complexes. Subsequent fractionation of interacting
proteins, followed by trypsinisation and mass spectrometric analysis
of peptides (Fig. 3) identified Sall4 (sal-like 4, a zinc-finger
transcription factor of the Spalt family) as a Nanog-interacting protein
(Wu et al., 2006). A conceptually similar approach based on the
biotinylation of transgenic constructs that encode a protein of interest
was used to identify multiple proteins that interact with Nanog and
Oct4 (Wang et al., 2006). This method (Fig. 3B), developed by
Strouboulis and colleagues (de Boer et al., 2003), uses ES cells that
express a biotin ligase encoded by the E. coli BirA gene (Driegen et
al., 2005). Stable transfection of these cells with expression constructs
that contain an additional 16 residues appended to the open reading
frame makes the encoded protein a ligase substrate and a biotin adduct
is added to a lysine residue within the tag. In order to minimally
perturb the transcription factor network, ES cell clones expressing the
additive transgenes at levels below those of the endogenous protein
were examined (Wang et al., 2006). In this way, the interaction of
Nanog with multiple transcription regulators was detected, including:
Sall4; Nr0b1 (nuclear receptor subfamily 0, group B, member 1);
Nac1 (nucleus accumbens associated 1; also known as Nacc1); Esrrb
(estrogen-related receptor beta; also known as Nr3b2); Zfp281 (zinc-
finger protein 281); Hdac2 (histone deacetylase 2) and Sp1. Oct4 was
shown to interact with an overlapping set of proteins, including Sall4,
Hdac2 and Sp1. Moreover an interaction between Nanog and Oct4
detected by mass spectrometry was confirmed in this study by co-
immunoprecipitation from transfected cell lysates by epitope tagging
(Wang et al., 2006). A separate study used a bacterially expressed
glutathione S-transferase-Oct4 fusion protein to pull down in vitro
translated Nanog with glutathione-conjugated beads (Liang et al.,
2008). These studies are illustrative of an on-going debate regarding
the relative merits of the different methods for determining protein-
protein interactions (Chatr-Aryamontri et al., 2008; Mackay et al.,
2007; Welch, 2009). Briefly, the concern is that protein interaction
data generated by affinity-based proteomic approaches of the type
outlined above are often validated by co-immunoprecipitation from
cell lysates. As conditions for co-immunoprecipitation can be varied
to ‘optimise’ the detection of an interaction (Mackay et al., 2007),
false-positive protein-protein interactions might be reported.
Computational methods can be used to set thresholds to eliminate false
positives (Chatr-Aryamontri et al., 2008). In the case of the Nanog-
Oct4 interaction, despite the fact that an interaction between
endogenous Oct4 and Nanog has yet to be confirmed, multiple
approaches have provided support for their interaction that exceeds
that available for any of the other protein-protein interactions of the
pluripotency network factors, other than Oct4 and Sox2. Ultimately,
biophysical methods will be required to rigorously characterise this
and other interactions.
The opposite problem, i.e. false negativity, appears to be
represented by the case of Smad1, which was not detected by mass
spectrometry (Liang et al., 2008; Wang et al., 2006) but did co-
Oct4 DNA element
ATTTGCAT WWCAAAG
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Fig. 2. The Oct/Sox DNA motif and the ternary structure of Oct-
Sox-DNA. (A) The DNA sites recognised by Oct4 and Sox2 are both
non-palindromic and might be expected to exist in four distinct relative
orientations. However, one of these orientations predominates at sites
that have been validated by reporter assays. (B) Nuclear magnetic
resonance (NMR) analysis of Oct1 bound to DNA shows two
conformations. (a) The sequence of a composite Oct/Sox site is
illustrated. (b) After binding of Oct1 to the DNA, the binary complex
exists in two conformations; the POU homeodomain (HD) contacts
DNA directly in both, but in only one is the POU-specific DNA-binding
domain (S) also in direct contact with DNA. (c) DNA binding by Sox2 via
its HMG DNA-binding domain (HMG) provides stabilising side-chain
interactions that lock POUS onto the DNA. (C) The ternary structure of
Oct1 (red) and Sox2 (green) bound to the Hoxb1 regulatory element
(blue DNA). The backbone position of residues, the side chains of which
provide stabilising interactions, are highlighted (yellow). Reprinted with
permission from Williams et al. (Williams et al., 2004).
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immunoprecipitate with Nanog (Suzuki et al., 2006). Such cases can
arise when the protein is poorly digested prior to mass spectrometry,
for instance because of a paucity of trypsin cleavage sites.
An additional screen for Nanog-interacting proteins was
conducted using an anti-Nanog antibody for affinity purification
from ES cells. Many of the proteins previously identified by Wang
et al. (Wang et al., 2006) were also detected in this study, including
Hdac2 (Liang et al., 2008). Interestingly, although Hdac2 is a
component of the nucleosome remodelling and histone
deacetylation (NuRD) complex (McDonel et al., 2009), several
proteins usually found in NuRD, including Rbbp7 (retinoblastoma
binding protein 7) and Mbd3 (methyl-CpG binding domain protein
3), were suggested to be present at substoichiometric levels relative
to the remaining NuRD components (Liang et al., 2008). This might
indicate that a particular and unusual form of NuRD associates with
Oct4 and Nanog, as the authors claim, or could reflect distinct
detection sensitivities for different NuRD subunits.
The affinity-based approaches summarised above have been
important in defining additional components of the transcriptional
machinery that Oct4 and Nanog interact with, and in several cases
iterative epitope tagging and affinity purification have further
extended the protein interaction network (Wang et al., 2006). Much
remains to be discovered about the mechanisms by which partners
interact. An important question concerns the significance of these
interactions in terms of pluripotent gene regulation, an issue we turn
to below.
Global localisation of pluripotency regulators to
chromatin
The list of Oct4 interactors identified in the biotin-based affinity
study (Wang et al., 2006) lacked one of the best-studied partners of
Oct4, namely Sox2. This might be because Oct4 and Sox2 interact
most stably when bound to adjacent sites on DNA. It is therefore
pertinent to ask which transcriptional regulators colocalise when
bound to DNA. In reality, this is hard to achieve at high resolution
on a global scale. However, initial studies have shown that OCT4,
SOX2 and NANOG frequently bind to sites that are closely localised
in the chromatin of human ES cells (Boyer et al., 2005).
Furthermore, Oct4 and Nanog have been found at closely localised
sites in mouse ES cells (Loh et al., 2006). Global colocalisation of
Oct4 and Sox2 might have been expected given the known co-
operative DNA binding of Oct4 and Sox2 (Ambrosetti et al., 1997).
However, there were no experimental data to predict the close
localisation of Nanog with Oct4 and Sox2. Subsequent large-scale
chromatin immunoprecipitation studies have shown that the close
localisation of Nanog with Oct4 and Sox2 is not peculiar to Nanog
but is shared with several other pluripotency transcription factors,
including Klf4 (Kruppel-like factor 4), Esrrb and Tcf4 (T cell factor
4) (Chen et al., 2008b; Cole et al., 2008; Kim et al., 2008).
Large-scale global localisation studies generally follow protocols
that consist of two stages. In the first stage, chromatin associated
with a protein of interest is purified using an affinity-based approach
akin to the techniques discussed in the previous section; this step is
generally referred to as chromatin immunoprecipitation (ChIP). In
the next stage, the DNA associated with the protein of interest is
purified and analysed. Analysis can either be by direct sequencing
(ChIP-seq) or by the hybridisation of DNA to a microarray of
genomic fragments (ChIP-on-chip, or ChIP-chip). In the ensuing
discussion, we focus on two studies that exemplify the issues raised
by these approaches. In the first (Kim et al., 2008), a ChIP-chip
approach was followed that used ES cell lines previously generated
by the bio-tagging strategy (Wang et al., 2006). In the second
approach (Chen et al., 2008b), ChIP-seq was used on a single
ES cell line. Target proteins were collected by conventional 
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Fig. 3. Affinity-based methods for identifying interacting proteins. (A,B) Modification of a transcription factor (TF) using epitope tags. (A) The
TF open reading frame is modified by in-frame fusion to an epitope tag encoding the so-called Flag peptide against which antibodies are
commercially available. (B) A 16-residue tag (BIO) added to the TF is a substrate for biotinylation when expressed in cells that are engineered to
express the E. coli BirA gene, which encodes a biotin ligase. (C) Affinity purification and partner identification strategy. Nuclear extracts are prepared
from ES cells that express an epitope-tagged (Ep) form of a TF under conditions in which binding of TF-interacting proteins to the TF is maintained.
Protein complexes are then incubated with an affinity reagent (anti-Flag IgG or streptavidin) that is immobilised on a solid support. After washing to
remove contaminating proteins, the captured proteins are separated by electrophoresis, excised from the gel, digested with protease and peptides
identified by mass spectrometry. PAGE, polyacrylamide gel electrophoresis.
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affinity purification using multiple antibodies, each specific 
for a given target protein, which could therefore be recognised
in its native state (Fig. 4).
Each of these techniques offers particular advantages. Of note,
the use of epitope tagging means that chromatin precipitation is not
subject to the variable efficiency inherent to the use of antibodies
raised against native proteins that can have significant differences
in their affinity and may have differential access to epitopes present
in multi-protein complexes. Conversely, transgene addition alters
the dose of the transcription factor of interest. Therefore, it is
important to analyse lines that minimally alter the total expression
level when the aim is to isolate partners that interact with the
transcription factor at endogenous expression levels. It is possible
that the interaction of a protein of interest with a partner protein
might be disrupted by the addition of an epitope. If chromatin
localisation is dependent upon such co-binding, then a site of
localisation will be missed. In practical terms, a distinct ES cell line
must be generated for each protein to be analysed. The affect of this
is clear from a comparison of the range of proteins studied by each
approach (Table 1). In addition to Oct4, Nanog and Sox2, the
proteins examined by Kim et al. (Kim et al., 2008) included the
transcriptional regulators Nr0b1, Nac1 and Zfp281, which the
authors had previously demonstrated to interact in solution with
Nanog (Wang et al., 2006). Other proteins studied included Klf4 and
c-Myc, proteins that together with Oct4 and Sox2 reprogram
somatic cells to a pluripotent state (Takahashi and Yamanaka, 2006),
and the Oct4 target gene Zfp42 (zinc-finger protein 42, also known
as Rex1) (Ben-Shushan et al., 1998). Chen et al. (Chen et al., 2008b)
chose to examine numerous proteins that: are implicated in the
control of ES cell self-renewal [Nanog, Oct4, Sox2, Esrrb and Zfx
(zinc-finger protein, X-linked)]; contribute to the reprogramming of
somatic cells to a pluripotent state [Klf4, c-Myc, n-Myc (Mycn)];
that regulate cell cycle progression [E2F1 (E2F transcription factor
1)]; insulate transcriptional domains [Ctcf (CCCTC-binding zinc-
finger protein)]; co-activate transcription [p300 (300 kD histone
acetyltransferase); Ep300]; are components of Polycomb repressive
complexes [Suz12 (suppressor of zeste 12 homologue)]; or are
preferentially upregulated in ES cells [Tcfcp2l1 (transcription factor
CP2-like 1)]. Additional proteins examined by Chen et al. include
the major mediators of the signalling pathways that lie downstream
of the identified extracellular signals required to maintain ES cells
in basal culture media, including BMP-induced Smad1 and LIF-
Transfect with 
tagged TF 
Incubate with streptavidin 
Cross-link proteins to 
chromatin and sonicate 
Reverse cross-linking, purify DNA and hybridise 
to a promoter microarray 
Cross-link proteins to 
chromatin and sonicate 
Incubate with anti-
TF antibody 
Map TF binding 
sites to genome 
Reverse cross-linking, purify 
DNA and analyse by Solexa 
BA
ES cells 
BirA  
ES cells 
Chromatin 
enriched for TF 
Chromatin 
enriched for TF 
Fig. 4. Global chromatin immunoprecipitation (ChIP) methods. A comparison of the (A) ChIP-seq and (B) ChIP-chip approaches. (A) ES cells
that express genes (green) encoding the protein to be analysed are treated with a reagent that cross-links chromatin-associated proteins to DNA.
Chromatin is then prepared from the cells and sonicated to reduce the average size of the DNA fragments. Various chromatin-associated proteins
(coloured shapes) are bound to the DNA (double wavy lines), including the protein of interest, which is shown in green bound to its target DNA
(also in green). The sonicated chromatin is incubated with an antibody against the protein of interest and the antibody-chromatin complexes are
then collected after incubation with anti-Ig immobilised on a solid support, centrifugation and washing. This enriches for both the target protein
relative to other chromatin-associated proteins and its associated target DNAs (shown in green). After reversal of cross-links, the DNA is purified and
analysed by Solexa sequencing and the signals corresponding to binding sites mapped to the genome (see Fig. 5). (B) ES cells that express the biotin
ligase gene BirA are transfected with an expression construct that encodes a tagged version (blue) of the protein of interest (green; see Fig. 3B).
Chromatin is then prepared from the BirA line and the derivative line expressing the protein of interest and is processed as in A, except that
sonicated chromatin is incubated with streptavidin coupled to a solid phase. Following the collection and washing of streptavidin-coupled
chromatin, protein-DNA cross-links are reversed and the purified DNA is hybridised to a microarray of promoter fragments that typically extend
from +8 to –2 kb relative to the transcription initiation site of a subset of genes.
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induced Stat3. Thus, this approach allows more proteins to be
examined, as multiple ES cell lines need not be derived and because
commercially available antibodies can be used in the analysis.
ChIP-seq and ChIP-chip location data analysis:
factors to consider
Comparisons between multiple, apparently similar ChIP
experiments can produce a weaker than expected overlap, raising
concerns about the reliability of the results that have been obtained
(Mathur et al., 2008). The outcomes of ChIP analyses depend
heavily on optimised experimental conditions. Variables include the
state of the cells at the time of harvest, antibody quality, the
performance of the array or sequencing method used and the data
analysis methods applied. It is therefore important to consider how
best to assess the biological importance of results from genome-
scale ChIP experiments.
Results consistency
One way to examine the reproducibility of target predictions from
ChIP experiments is to integrate results from different studies. In the
large-scale studies discussed above, Kim et al. (Kim et al., 2008)
used a promoter array that reports binding close to the predicted
transcription start site of genes printed on the chip. Sequencing-
based methods do not have this bias and report binding throughout
the genome. For example, using ChIP-PET (a variant of ChIP-seq
in which sequence tags are generated from both ends of cloned ChIP
fragments), only 18.6% of Oct4 and 12.8% of Nanog binding sites
were found within 10 kb of a predicted transcription start site (Loh
et al., 2006). Therefore, the vast majority of potential binding sites
might be missed in studies based on promoter arrays. Such design
issues are compounded by differences in the experimental and
analytical approaches used in different laboratories.
However, ChIP-seq and ChIP-chip studies can be compared if the
comparison is restricted to target sequences present on the
microarray used for ChIP-chip (Fig. 5). In the case of the Kim and
Chen studies (Kim et al., 2008; Chen et al., 2008b), ~50% of the
binding targets of c-Myc, Nanog or Sox2 identified by Chen et al.
were also found by Kim et al. However, only ~20% of the Oct4
binding targets identified by Chen et al. were found by Kim et al.
These overlaps are encouraging, considering the relatively simple
method we have used to combine the data. It is possible that more
sophisticated approaches might yield an increase in such overlaps.
However, these analyses highlight the issue of using the output from
an individual study, from which many putative targets might be
followed erroneously.
Thresholding and prioritising ChIP targets
The purpose of ChIP analyses is to attempt to identify all the
binding sites for a given transcription factor in the genome. During
ChIP, the aim is to enrich DNA sequences that specifically bind a
given transcription factor. In practice, a population of DNA
fragments is enriched that vary in length and have random ends but
which centre around the site of interest. These enriched ChIP
fragments must be distinguished from the pattern of fragments
obtained from controls.
In the microarray study (Kim et al., 2008), ChIP fragments were
hybridised to an array of oligonucleotides designed against promoter
regions. Signals from adjacent oligonucleotides generate
hybridisation signals that represent putative transcription factor
locations. Comparison of these putative locations with signals
generated from the BirA control cell line is made together with
standardisation of signal peak intensities with reference to the copy
number, sequence composition and repeat distribution of all the
oligonucleotides on the microarray (Johnson et al., 2006). Final
assignment of a signal peak to a potential target gene is performed
directly based on the identity of the well-characterised gene printed
on the chip. In the ChIP-seq study (Chen et al., 2008b), transcription
factor binding sites were identified by clustering DNA sequence
outputs generated from the ChIP sample. This identifies potential
transcription factor binding sites that are then compared with signal
peaks computed from randomised data. Chen et al. also used an anti-
GFP ChIP to account for sequences that give an elevated signal in
controls (e.g. microsatellites) that cannot be accounted for by their
computational model. Signal peaks from ChIP-seq experiments are
commonly assigned to the nearest gene using a threshold that defines
the fixed maximum distance between a binding site and an associated
transcription initiation site. To avoid applying such an arbitrary
threshold, Chen et al. calculated a transcription factor binding
site/gene association score from the observed relationship of each
transcription factor binding site with its proposed target gene and the
distribution of the relevant recognition sites in randomised sequence.
In this way, different association thresholds for each transcription
factor between signal peak and assigned genes could be calculated.
Validation of genome-scale ChIP data
Both ChIP-chip and ChIP-seq have fantastic potential to identify
transcription factor target genes and so to elucidate transcription
factor networks. It is common practice to rank target lists from ChIP
experiments using a variety of parameters, such as the probability of
enriched binding, the number of tags that map to a particular gene,
the proximity to transcription start sites or other gene regulatory
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Table 1. Comparison of proteins identified in two large-scale
global localisation studies
Kim et al. Chen et al.
Protein Bio-ChIP-chip ChIP-seq
Oct4 Y Y
Sox2 Y Y
Nanog Y Y
Klf4 Y Y
c-Myc Y Y
n-Myc Y
Stat3 Y
Smad1 Y
Ctcf Y
Nr0b1 Y
E2F1 Y
Esrrb Y
Nac1 Y
p300 Y
Zfp42 Y
Suz12 Y
Tcfcp2l1 Y
Zfp281 Y
Zfx Y
Data are from Kim et al. (Kim et al., 2008) and Chen et al. (Chen et al., 2008b).
Y indicates that the protein was localised using that technique.
c-Myc (Myc), myelocytomatosis oncogene; Ctcf, CCCTC-binding factor; Esrrb,
estrogen-related receptor beta; E2F1, E2F transcription factor 1; Klf4, Kruppel-like
factor 4; n-Myc (Mycn), v-myc myelocytomatosis viral related oncogene,
neuroblastoma derived (avian); Nac1 (Nacc1), nucleus accumbens associated 1;
Nanog, Nanog homeobox; Nr0b1, nuclear receptor subfamily 0, group B, member
1; Oct4, octamer 4; p300 (Ep300), 300 kD histone acetyltransferase; Smad1, MAD
homolog 1; Sox2, SRY-box containing gene 2; Stat3, signal transducer and activator
of transcription 3; Suz12, suppressor of zeste 12 homolog; Tcfcp2l1, transcription
factor CP2-like 1; Zfp42 (Rex1), zinc-finger protein 42; Zfp281, zinc-finger protein
281; Zfx, zinc-finger protein X-linked.
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features. In general, the relationship of these features to actual gene
expression is unknown. Attempts have been made to build models
to address this problem (e.g. Sharov et al., 2008) but, of course, it
might be unlikely in practice that the functional activity of a given
transcriptional regulator can be generally described for all genes
because gene-specific factors, such as additional transcription factor
binding sites, strongly influence gene expression. In addition,
candidate genes for validation are almost never selected randomly
but with reference to a body of existing knowledge. It is therefore
impossible to use these validated genes to estimate the overall
number of true positives in the candidate list.
Initial validation of genome-scale ChIP data is often performed
by comparing microarray-based estimates of the transcription level
of the gene to which the transcription factor binding site has been
mapped. Concordance between transcription factor binding and
gene expression under conditions in which the transcription factor
level is modulated can then be used to identify target genes for
specific transcription factors. It is instructive to reconsider the basic
assumptions of this approach. Take, for example, Oct4. Depletion of
Oct4 by RNAi (Loh et al., 2006) or by using the tetracycline-
suppressible Oct4 cell line ZHBTc4 (Niwa et al., 2000) causes
trophectodermal differentiation. Under differentiation conditions,
direct targets of Oct4 may be modulated, together with indirect
targets and with the associated additional epigenetic changes that
occur as cells exit the ES cell state. Critically, these changes affect
the accessibility of chromatin to transcription factors and might
result in alterations in background binding (Rozowsky et al., 2009).
This could lead to an artefactual association between differentially
regulated genes and transcription factor localisation.
To avoid such spurious associations between transcription factors
and non-target genes, one approach is to examine early
transcriptional events, before wholesale epigenetic changes set in.
In this case, the observation (Chen et al., 2008b; Kim et al., 2008;
Loh et al., 2006) that many key ES cell-specific genes have multiple
regulatory inputs from different transcription factors is of major
importance. In a complex interconnected network, modulation of
one input might not be sufficient to cause a change in transcription.
An example of this can be seen in ZHBTc4 cells upon repression of
Oct4; the levels of Sox2 and Nanog are unaffected until at least 24
hours after Oct4 is downregulated (Sharov et al., 2008). Many other
genes are modulated before these two key Oct4 targets finally begin
to show reduced expression. Another approach to validation is to
identify direct changes in gene expression by blocking translation
(e.g. with cycloheximide) and to map these changes to ChIP binding.
However, cycloheximide-treated cells are far from being in a
physiological state. Moreover, a transcription factor that is bound
directly to a target gene might require the translation of an unstable
co-factor to become active.
These complexities mean that in practice it is difficult to connect
transcriptional regulation to ChIP binding, which might partly
account for the weak overlap observed between these two types of
data in published studies. The proximity of a transcription factor
binding site to a gene obviously does not guarantee that the binding
of the transcription factor will have a functional consequence for that
gene, a more distant gene or, indeed, for any gene (Sharov et al.,
2008). Many other parameters need to be considered, such as local
chromatin structure and the binding of co-regulators, before accurate
predictions can be made. In the future, it will be desirable to develop
methods for ranking ChIP binding sites based upon the likelihood
that these sites will participate in gene regulation. This might emerge
by calculating general ‘rules’ from large validated data sets and by
integrating experimental data that map out the details of the local
genomic context of the binding sites.
Conclusions from genome-wide transcription
factor localisation studies
Each of these studies arrives at some distinct conclusions. However,
the agreement between the studies is revealing. Both studies (Chen
et al., 2008b; Kim et al., 2008) identify specific genomic regions that
bind multiple distinct transcription factors: more than 100 promoters
are occupied by seven or more transcriptional regulators and ~1000
promoters bind four or more of these proteins. In fact, the number
of genes that are targets for the binding of multiple transcriptional
Exclude genes not potentially 
reported by both technologies 
Cluster to genome, 
detect peaks in 
binding position 
Associate peak with
gene on chip
Cluster sequence 
and map to genome 
Associate peak with
nearest gene 
A Kim et al. Chen et al. 
1855 1112 1049 
843 500 516 
c-Myc [360 excluded]  B Oct4 [526 excluded]  
588 190 770 
623 253 269 
Nanog [1392  excluded]  Sox2 [696 excluded]  
Fig. 5. Overlap in data between large-scale global localisation
studies. (A) Workflow for ChIP-chip and ChIP-seq studies and
comparison of outputs. (B) Overlap of target genes obtained for
biotinylated c-Myc, Nanog, Oct4 and Sox2 from the studies of Kim et
al. (blue) (Kim et al., 2008) and Chen et al. (yellow) (Chen et al.,
2008b). To facilitate a comparison of data from the two studies, the
mapping of target genes to peak binding positions was recalculated
from the reported peak locations. Peaks were assigned to the nearest
gene, as annotated in the Ensembl v46 mouse genomic data. Target
peaks were only considered if they were in genomic regions
measured by both the promoter array and the ChIP-seq study. The
number of genes with ChIP-seq peaks within 10 kb of the
transcription initiation site but not mapped to the microarray are
shown as excluded counts.
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regulators greatly exceeds the number that would be predicted by
chance. A similar increase in the number of genes bound by multiple
transcription factors above that expected randomly was observed in
a global localisation study of human hepatic cells (Odom et al.,
2006). Therefore, the binding of multiple factors appears to have
been selected for and is likely to be biologically significant. Whether
the apparent co-incident binding reflects direct protein-protein
interaction or mere proximity is unclear. Higher resolution analyses
will be required to distinguish between these possibilities.
Nevertheless, the possibility that transcription factors colocalise
through direct protein-protein interactions is entirely in line with the
concept of the combinatorial control of gene expression (Ptashne
and Gann, 2001).
In general, it would appear that target genes bound by one or a few
proteins are inactive or repressed, whereas target genes bound by
four or more factors are active and become repressed upon
differentiation. Kim et al. (Kim et al., 2008) used supervised
clustering algorithms, which order target genes based upon their
potential binding sites, to ask which target genes bound only one of
the examined proteins. The largest group was genes that bound c-
Myc. Moreover, most genes to which a single protein bound
appeared to be repressed. It will be interesting to see how many of
these genes have subunits of repressive complexes colocalised with
the identified transcription factor. In this context, it is notable that
subunits of the repressive NuRD complex have been reported to
interact with Oct4 and Nanog (Liang et al., 2008; Wang et al., 2006).
An alternative explanation for the association of lone binders with
non-expressed genes is that these associations represent false
positives in the localisation analyses. Finally, some lone binders
might perform more interesting roles. Some transcription factors,
such as the forkhead box, winged helix transcription factor FoxA1,
that positively regulate transcription in differentiated cells can act as
‘pioneer’ factors, which are able to enter compact chromatin and
make it more accessible (Cirillo et al., 2002). A Fox family member
expressed in ES cells (FoxD3) can be detected by ChIP in the same
region of the albumin enhancer to which FoxA1 binds in liver. This
binding has been proposed to maintain unmethylated cytosines
necessary to keep the site in a state compatible with normal
development (Xu et al., 2007). The protein for which the evidence
of a repressive function associated with lone binding looks least
convincing is Oct4 (Kim et al., 2008). This could indicate that Oct4
is unique among these molecules in acting independently as a gene
activator or that there are additional, unstudied Oct4 partner proteins
that act in combination with Oct4 at these sites.
In addition to the redundancy of Sox proteins already mentioned
(Masui et al., 2007), redundancy between other transcription factor
families is likely. For example, a Klf4 binding site identified at the
Nanog promoter (Chen et al., 2008a) has previously been suggested
to be a site at which Klf5 acts (Parisi et al., 2008). Klf2, Klf4 and Klf5
have also been shown to exhibit overlapping binding site localisation
(Jiang et al., 2008). However, it is also possible that such sites bind
related Klf transcription factors or, indeed, Sp1 family members. In
this regard, it is notable that Sp1, but not Klfs, were detected as Oct4
and Nanog partner proteins in solution (Wang et al., 2006).
A second major conclusion concerns the relationship of c-Myc to
the core pluripotency factors. At the outset of these two studies
(Chen et al., 2008b; Kim et al., 2008), the authors might have
expected to unearth some commonality to explain the roles of c-Myc
and Oct4/Sox2/Klf4 during somatic cell reprogramming. In fact the
opposite is the case. Both studies found that although there are many
genes that are common targets for Nanog, Oct4, Sox2 and Klf4, the
genes that c-Myc localises to overlap less with these targets. c-Myc
binding regions also have distinctive histone marks (Kim et al.,
2008). Targets of c-Myc, along with those of Nac1 and Zfp42, are
enriched for H3K4(me)3, a modification that is characteristic of
‘active’ genes, and are depleted for the ‘inactive’ histone
H3K27(me)3 mark. By contrast, genes to which Nanog, Oct4, Sox2,
Nr0b1 and Klf4 are bound are relatively enriched for both of these
marks and for H3K4(me)3 in particular. This profile of histone marks
that are associated both with gene transcription and repression is
often referred to as ‘bivalency’ and occurs at many promoters in ES
cells (Azuara et al., 2006; Bernstein et al., 2006).
A functional distinction between the Myc binding sites and the
sites to which the core pluripotency factors bind was also revealed
in the Chen et al. study (Chen et al., 2008b). The transcriptional co-
activator p300 predominantly localises to genomic sites that bind
Nanog, Oct4 and Sox2, but not to sites that bind Myc. Moreover, the
Weeder algorithm, which searches for enriched motifs in sets of
sequences, detected an Oct/Sox composite sequence motif in the
p300 binding site data. Genomic fragments covering 25 of the
Oct4/Nanog/Sox2 clusters and eight of the Myc clusters were
therefore isolated and tested for enhancer activity. All of the
Oct4/Nanog/Sox2 clusters showed transcriptional activity (Fig. 6).
The context in which the Oct4/Nanog/Sox2 binding sequences act
is clearly important because the magnitude of the enhancer effects
varied over an order of magnitude within the set of 25 test cases.
Importantly, none of the Myc localisation sites had enhancer activity,
further underpinning the idea that Myc functions in a way that is
distinct from the other core pluripotency factors.
Several other aspects of these analyses warrant consideration. By
analysing colocalisation frequency, distinct categories of colocalised
binding can be seen, in addition to the major Myc and
Oct4/Nanog/Sox2 clusters. Somewhat surprisingly, the protein most
often colocalised with Sox2 is not Oct4, but rather Nanog (Chen et
al., 2008b). It will be interesting to see whether there is a binding
relationship between Nanog and Sox2 that can explain this
observation. In addition, Klf4, Esrrb and Tcfcp2l1 also appear to
colocalise to a significant proportion of sites to which neither Myc
nor Oct4/Nanog/Sox2 bind. This might in part explain the ability of
Esrrb to substitute for Klf4 during somatic cell reprogramming
(Feng et al., 2009), although it should be noted that Tcfcp2l1 was
tested in the same assay without success. Colocalisation is also
apparent between Smad1 and Oct4/Nanog/Sox2, harking back to the
protein interaction between Nanog and Smad1.
Global localisation studies during somatic cell
reprogramming
Recently, the relevance of these kinds of study to reprogramming
has been addressed by comparing the global localisation of Oct4,
Sox2, Klf4 and c-Myc in ES cells, induced pluripotent stem (iPS)
cells and partially reprogrammed cells (Sridharan et al., 2009). In
partially reprogrammed cells, binding targets of Oct4, Sox2 or Klf4
that also bound c-Myc had a generally similar binding profile to
those seen in ES and iPS cells. However, genes bound only by Oct4,
Sox2 and Klf4 in ES and iPS cells were, in most cases, unoccupied
by these proteins in partially reprogrammed cells. These results
suggest that partially reprogrammed cells are locked in a state in
which an additional event is necessary to facilitate the binding of
pluripotency transcription factors.
This study also suggested that c-Myc acts early during
reprogramming, at least in part to repress the expression of fibroblast
genes, and that c-Myc might therefore function before
Oct4/Sox2/Klf4. These effects of Myc expression might be a result
of global alterations in chromatin, such as histone acetylation
REVIEW Development 136 (14)
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(Knoepfler et al., 2006), and in this respect it is noteworthy that
inhibition of histone deacetylases can replace c-Myc in
reprogramming (Huangfu et al., 2008).
Molecules involved in reprogramming may function in an
analogous fashion to pioneer factors such as FoxA1 and Gata4 (a
member of a family of zinc-finger transcription factors that
recognise GATA motifs), which operate on the albumin enhancer
during ES cell differentiation to open up compacted nucleosomal
arrays (Cirillo et al., 2002). Although c-Myc has been shown to
regulate global chromatin structure in neural cells (Knoepfler et al.,
2006), whether it can function in an entirely analogous fashion to
FoxA1 is unknown; perhaps another pluripotency factor(s) might
have this capacity.
Transcription factor co-dependency of enhancer
function
Proteins binding to enhancers exhibit co-operative DNA binding
(Merika and Thanos, 2001). Oct4 and Sox2 bind DNA co-
operatively (Ambrosetti et al., 1997; Ambrosetti et al., 2000), but do
any other pluripotency transcription factors show co-dependent
DNA binding? First, consider the DNA binding of individual factors.
To determine the in vivo sequence specificity of the transcription
factors, sequences ±100 bp from the top 500 binding peaks for each
factor were selected, repeats were masked and then searched for
over-represented sequences (Chen et al., 2008b). Not unexpectedly,
the sequences that underlie the DNA fragments bound by Oct4 and
Sox2 were extremely similar, indicating that Oct4 and Sox2 most
often act together in the relative orientation illustrated in Fig. 2.
More surprising was the finding that a similar Oct4/Sox2 sequence
motif underlies DNA bound by both Nanog and Smad1.
The clustering of Smad1 with Oct4, Nanog and Sox2 is
interesting given that Smad1 is an intermediary in BMP signalling
and that the positive effect of BMP on ES cell self-renewal can be
accounted for by the Id (inhibitor of differentiation) genes. Ids are
transcriptional modulators that sequester pro-neural basic helix-
loop-helix proteins into non-functional complexes (Ruzinova and
Benezra, 2003). In ES cells, Id3 expression is stimulated ~6-fold
by BMP treatment (Ying et al., 2003). In this regard, a
Nanog/Oct4/Sox2 binding locus 1.5 kb upstream of the Id3 gene has
been described that also binds Smad1 (Chen et al., 2008b). This is
significant because it suggests that some loci can bind multiple
transcriptional regulators (ten in the case of Id3) yet remain
responsive to further transcriptional activation. Id3 might be an
example of a gene that binds multiple factors without being equally
responsive to all of them, but further work will be required to
determine this. A related question is whether there are target genes
that are bound by many of the transcriptional regulators but which
remain unexpressed without recruitment of a key activating
transcription factor.
In contrast to the situation for Smad1, a canonical binding site for
Stat3 is found for Stat3 binding loci, suggesting that Stat3 might be
more weakly associated with the Oct/Sox motif than is Smad1.
Nevertheless, some Stat3 targets are co-bound by Oct4/Nanog/Sox2.
Interestingly, for both Oct4/Smad1 and Oct4/Stat3 co-bound
regions, the depletion of Oct4 over 2 days resulted in a reduction in
Smad1 or Stat3 binding at these sites (Chen et al., 2008). If this
analysis was performed prior to differentiation-induced loss of
additional transcription factors, this result indicates that Stat3 and
Smad1 binding to the test loci is Oct4-dependent. By contrast,
perturbations in Smad1 or Stat3 did not affect Oct4 binding. The
transcriptional co-activator p300 is almost exclusively localised to
Oct4/Nanog/Sox2 as opposed to c-Myc targets. With the proviso
mentioned above, p300 binding appears to be dependent upon
Oct4/Nanog/Sox2 because depletion of any one of these proteins
reduces p300 binding.
The issue of co-dependent binding has also been examined in a
few gene-specific studies. Using ZHBTc4 cells, in which Oct4
protein can be eliminated by 12 hours of tetracycline treatment
(Niwa et al., 2000), the binding of Esrrb to the Nanog promoter was
found to be dependent upon Oct4 binding to a composite Oct/Sox
site situated 11 bp downstream of the Esrrb binding site (van den
Berg et al., 2008). In vitro studies indicate that DNA binding by
Esrrb is co-operative with Oct4/Sox2. This proximity of the Esrrb
binding site to the non-palindromic Oct/Sox site suggests that Esrrb
makes direct, sterospecific contact with Oct4. However, the binding
of Esrrb to other Oct/Sox target genes did not reveal the existence of
a simple spatial relationship between DNA recognition sites (van
den Berg et al., 2008). Zfp143 (zinc-finger protein 143) also binds
to the proximal Nanog promoter, ~90 bp upstream of the Oct4 site
(Chen et al., 2008a). In this case, RNAi depletion of Zfp143 caused
a reduction in the localisation of Oct4 (but interestingly not of Sox2)
at Nanog prior to the downregulation of Oct4 protein (Chen et al.,
2008a).
Co-dependency of binding extends to Xist, the clearest example
to date of a gene that is repressed by the pluripotency factors. ChIP
identified an Oct4/Sox2/Nanog binding site within the first intron of
Xist, where the pluripotency factors are responsible for repression
of Xist and, consequently, for the activation of both X chromosomes
in female ES cells (Navarro et al., 2008). In ZHBTc4 cells depleted
of Oct4, Xist expression is massively upregulated and Nanog and
Sox2 are lost from the Xist chromatin at a time when the Nanog and
Sox2 mRNAs are still expressed. By contrast, Nanog-null ES cells
express Xist at ~5-fold the level of wild-type male ES cells, and Oct4
and Sox2 remain bound to the Xist intron. This co-dependence of
binding to Xist is interesting in view of the fact that Oct4 and Sox2,
but not Nanog, are expressed in cells of the early female embryo in
which the paternal X chromosome is inactive. Nanog may be
required to facilitate Oct4/Sox2 binding to Xist either by recruitment
or by erasure of an epigenetic imprint (Navarro et al., 2008; Navarro
and Avner, 2009). There is a similarity here to the situation in
partially reprogrammed iPS cells, which, like the early embryo, lack
Nanog expression (Sridharan et al., 2009). It is possible that Nanog
Pol II 
complex 
Esrrb 
STAT3 
Zfp281 Klf 
Sox 
Smad 
Oct4 
Nanog Nanog 
Fig. 6. Illustration of an active promoter in ES cells. Pluripotency
transcription factors are shown bound to an enhancer sequence
upstream of the transcription initiation site of an associated gene
(indicated by the arrow). Two monomeric subunits of Nanog are
illustrated to reflect the fact that Nanog is active in dimeric form (Mullin
et al, 2008; Wang et al, 2008). Contact between enhancer-bound
transcription factors and the RNA polymerase II (Pol II) complex
machinery occurs through a bridging interaction with the p300
transcriptional co-activator.
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facilitates full reprogramming of partially reprogrammed cells
through a similar mechanism to that which operates in early
embryonic cells.
These studies suggest that a hierarchy of transcription factor
binding to ES cell enhancers occurs. Oct4 might nucleate the
binding of the other factors, but the example of Zfp143 mentioned
above indicates that more data need to be analysed before reliable
rules concerning the co-dependencies of transcription factor binding
to enhancers, or indeed to Myc localisation sites, can be proposed.
The global localisation studies we have discussed place Oct/Sox
motifs at the centre of the pluripotency network. However, the Sox2
deletion studies mentioned above serve as a reminder that there is
still much to learn about the details of the pluripotency network.
Sox2 deletion in ES cells appears to phenocopy Oct4 deletion
(Masui et al., 2007). Consistent with this, the Sox2 deletion
phenotype can be rescued by Oct4 expression. The Oct4 gene
contains a validated Oct/Sox motif in its promoter but Oct/Sox
reporters continue to be expressed in Sox2-deleted cells, which is
likely to be due to redundancy of function between Sox proteins
(Masui et al., 2007). The mechanism proposed to account for the
effects of Sox2 on Oct4 gene expression involves indirect effects
mediated by Nr5a2 and Nr2f2, although this hypothesis remains to
be tested. Critically, however, these considerations do not mean that
the Oct/Sox motif is unimportant in the regulation of Oct4
expression. A proper understanding will only emerge from
functional studies on ES cells in which the DNA-binding motifs for
each of the above-mentioned transcription factors are mutated and
the consequences established.
Conclusions
Global studies of protein localisation to specific chromatin sites
present us with a wealth of information on the transcriptional control
of cell identity and have revealed previously unsuspected potential
working relationships between transcription factors. The supposition
is that many of the proteins that bind in proximity to each other are
in direct contact with one another, but this remains to be established
both generally and for particular loci. Additional challenges include
determining the binding dependencies of individual proteins to
particular loci in order to discover whether there are global rules
governing all assemblies. However, it seems likely that there will be
significant variation in the manner in which assemblies of
transcription factors are constructed at individual loci (Fuxreiter et
al., 2008), and that the details of this variation will critically
determine the transcription pattern of the associated gene. Finally,
the question of what determines activation versus repression remains
an open issue.
Although we have focused here on studies using mouse ES cells,
it will be important to understand how these findings relate to human
ES cell studies. Studies on human ES cells may be best compared
with studies on pluripotent mouse epiblast stem cell (EpiSC) lines,
which have been established from post-implantation embryos
(Brons et al., 2007; Tesar et al., 2007). ES cells and EpiSCs differ
from one another in their factor requirements in vitro and in their
capacity to incorporate into developing chimaeras. The recent
demonstration of revertibility of EpiSCs to an ES cell state is
relevant here (Guo et al., 2009). A related issue concerns the
heterogeneity of the Oct4-expressing ES cell population with respect
to its expression of pluripotency transcription factors, such as
Nanog, Zfp42 and Stella (Dppa3) (Chambers et al., 2007; Hayashi
et al., 2008; Toyooka et al., 2008). Understanding how transcription
factor assemblies change as cells move from one pluripotent
compartment to another will allow us to view how the dynamic
alterations in cell phenotype that underlie developmental transitions
are dictated, which will surely strengthen our ability to bend these
cells to our will.
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